Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury
Open Access
- 9 June 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 48 (4), 1087-1096
- https://doi.org/10.1002/hep.22444
Abstract
Adiponectin is an adipocyte-derived hormone with a wide range of beneficial effects on obesity-related medical complications. Numerous epidemiological investigations in diverse ethnic groups have identified a lower adiponectin level as an independent risk factor for nonalcoholic fatty liver diseases and liver dysfunctions. Animal studies have demonstrated that replenishment of adiponectin protects against various forms of hepatic injuries, suggesting it to be a potential drug candidate for the treatment of liver diseases. This study was designed to investigate the cellular and molecular mechanisms underlying the hepatoprotective effects of adiponectin. Our results demonstrated that in adiponectin knockout (ADN-KO) mice, there was a preexisting condition of hepatic steatosis and mitochondrial dysfunction that might contribute to the increased vulnerabilities of these mice to secondary liver injuries induced by obesity and other conditions. Adenovirus-mediated replenishment of adiponectin depleted lipid accumulation, restored the oxidative activities of mitochondrial respiratory chain (MRC) complexes, and prevented the accumulation of lipid peroxidation products in ADN-KO mice but had no obvious effects on mitochondrial biogenesis. The gene and protein levels of uncoupling protein 2 (UCP2), a mitochondrial membrane transporter, were decreased in ADN-KO mice and could be significantly up-regulated by adiponectin treatment. Moreover, the effects of adiponectin on mitochondrial activities and on protection against endotoxin-induced liver injuries were significantly attenuated in UCP2 knockout mice. Conclusion: These results suggest that the hepatoprotective properties of adiponectin are mediated at least in part by an enhancement of the activities of MRC complexes through a mechanism involving UCP2. (HEPATOLOGY 2008.)Keywords
This publication has 48 references indexed in Scilit:
- Adiponectin Mediates the Suppressive Effect of Rosiglitazone on Plasminogen Activator Inhibitor-1 ProductionArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- NAD(P)H Oxidases Regulate HIF-2α Protein ExpressionPublished by Elsevier BV ,2007
- Nonalcoholic Fatty Liver Disease: From Steatosis to CirrhosisHepatology, 2006
- The Roles of Leptin and Adiponectin: A Novel Paradigm in Adipocytokine Regulation of Liver Fibrosis and Stellate Cell BiologyThe American Journal of Pathology, 2005
- Is Adiponectin Involved in the Pathogenesis of Nonalcoholic Steatohepatitis?Journal of Clinical Gastroenterology, 2005
- Uncoupling protein-2 and non-alcoholic fatty liver diseaseFrontiers in Bioscience-Landmark, 2005
- Increased adiposity and reduced adipose tissue mRNA expression of uncoupling protein‐2 in first‐degree relatives of type 2 diabetic patients: evidence for insulin stimulation of UCP‐2 and UCP‐3 gene expression in adipose tissueDiabetes, Obesity and Metabolism, 2004
- Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in miceHepatology, 2004
- Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitisHepatology, 2003
- Steatohepatitis: A tale of two “hits”?Gastroenterology, 1998